Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.

QJM : monthly journal of the Association of Physicians·2016

Same author

Synergistic effect of follicle-stimulating hormone receptor and androgen receptor gene variants on semen quality.

Andrologia·2012

Same author

Semen quality is influenced by androgen receptor and aromatase gene synergism.

Human reproduction (Oxford, England)·2012

Same author

The (TTTA)n polymorphism of aromatase (CYP19) gene is associated with age at menarche.

Human reproduction (Oxford, England)·2010

Same author

The (TAAAA)n polymorphism of the SHBG gene in men with the metabolic syndrome.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2010

Same author

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

Diabetologia·2010

Search research articles

Related Experiment Video

Updated: May 19, 2026

Identification and Dissection of Diverse Mouse Adipose Depots

Identification and Dissection of Diverse Mouse Adipose Depots

Published on: July 11, 2019

Adiponectin in diabetes mellitus.

N Xita¹, A Tsatsoulis

¹Department of Endocrinology, University of Ioannina, Ioannina, Greece.

Current Medicinal Chemistry

|August 11, 2012

Summary

Adiponectin, a key adipokine, protects against obesity

Area of Science:

Metabolic research
Endocrinology
Obesity studies

Background:

Adiponectin is a crucial adipokine with protective effects against obesity-related metabolic and cardiovascular issues.
It enhances insulin sensitivity by reducing hepatic gluconeogenesis and increasing glucose transport in muscles.
Adiponectin also boosts energy expenditure and fatty acid oxidation in peripheral tissues.

Purpose of the Study:

To explore the association between low adiponectin levels (hypoadiponectinemia) and insulin resistance/type 2 diabetes.
To investigate whether hypoadiponectinemia is a cause or consequence of these metabolic disorders.
To evaluate the therapeutic potential of enhancing adiponectin signaling for diabetes prevention and treatment.

Main Methods:

Review of clinical, experimental animal, and genetic studies.

More Related Videos

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro

Published on: December 5, 2025

Related Experiment Videos

Last Updated: May 19, 2026

Identification and Dissection of Diverse Mouse Adipose Depots

Identification and Dissection of Diverse Mouse Adipose Depots

Published on: July 11, 2019

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro

Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro

Published on: December 5, 2025

Analysis of drug mechanisms that improve insulin resistance by increasing adiponectin levels.

Main Results:

Strong evidence links hypoadiponectinemia with insulin resistance and type 2 diabetes.
Some drug classes improve insulin resistance, partly by elevating plasma adiponectin.
Adiponectin's role in insulin secretion and central energy expenditure is under investigation.

Conclusions:

Adiponectin's multifaceted actions suggest its importance in metabolic health.
Hypoadiponectinemia is closely associated with insulin resistance and type 2 diabetes.
Targeting adiponectin pathways presents a promising, yet complex, therapeutic strategy for diabetes.